TNFRSF8 and Hodgkins lymphoma: AFM13, a tetravalent chimeric antibody that targets CD30 and CD16A, has previously shown efficacy for Hodgkin’s lymphoma [148,149], and is currently being tested in a phase I clinical trial for R/R CD30+ lymphoid malignancies (NCT04074746).